<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3847">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338698</url>
  </required_header>
  <id_info>
    <org_study_id>12(06)/2016-Coord</org_study_id>
    <nct_id>NCT04338698</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shehnoor Azhar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Health Sciences Lahore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8hr&#xD;
      thrice a day for 5 days) vs oseltamivir (75 mg orally twice a day for 5 days) vs Azithromycin&#xD;
      (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and&#xD;
      in combination (in all seven groups), in clearing the coronavirus nucleic acid from throat&#xD;
      and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary&#xD;
      outcomes).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A scientific taskforce notified by the Ministry of Science and Technology of the Government&#xD;
      of Pakistan will oversee a comprehensive cohort study. Within this cohort, a multicenter,&#xD;
      adaptive, randomized controlled trial will evaluate, among eligible SARS-Cov-2 (COVID-19)&#xD;
      infected patients receiving standard supportive care who consent to randomization following a&#xD;
      new diagnosis in Pakistan, if Hydroxychloroquine Phosphate/Sulfate alone (control&#xD;
      intervention) vs a series of alternatives (comparator interventions) including Oseltamivir&#xD;
      and Azithromycin alone and in combination with Hydroxychloroquine Phosphate/Sulfate is&#xD;
      effective in clearing the coronavirus and improving the clinical course of the disease. Those&#xD;
      not consenting to randomization will be followed up for outcomes of SARS-Cov-2 infection with&#xD;
      supportive care only. Findings of this study are expected to inform clinical care and public&#xD;
      health protocols and policies for management of SARS-Cov-2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adaptive design (sample size given below is indicative)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory Result</measure>
    <time_frame>Day 07 on follow-up</time_frame>
    <description>The laboratory-based primary outcome will be turning test negative for COVID-19 on RT-qPCR calculated as viral load of &lt; 150 i.u</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>Day 07 on follow-up</time_frame>
    <description>The clinical primary outcome will be improvement of two points on a seven-category ordinal scale shown below:&#xD;
Not hospitalized, able to resume normal activities&#xD;
Not hospitalized, but unable to resume normal activities&#xD;
Hospitalization, not requiring supplemental oxygen&#xD;
Hospitalization, requiring supplemental oxygen&#xD;
Hospitalization, requiring noninvasive mechanical ventilation&#xD;
Hospitalization, requiring invasive mechanical ventilation&#xD;
Death</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>Control Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oseltamivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine + Azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine + Oseltamivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oseltamivir + Azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxyquinine + Oseltamivir + Azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Cohort</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-consenting to randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine Phosphate/Sulfate (200 mg orally thrice a day for 5 days)</description>
    <arm_group_label>Comparator 3</arm_group_label>
    <arm_group_label>Comparator 4</arm_group_label>
    <arm_group_label>Comparator 6</arm_group_label>
    <arm_group_label>Control Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Oseltamivir (75 mg orally twice a day for 5 days)</description>
    <arm_group_label>Comparator 2</arm_group_label>
    <arm_group_label>Comparator 4</arm_group_label>
    <arm_group_label>Comparator 5</arm_group_label>
    <arm_group_label>Comparator 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)</description>
    <arm_group_label>Comparator 1</arm_group_label>
    <arm_group_label>Comparator 3</arm_group_label>
    <arm_group_label>Comparator 5</arm_group_label>
    <arm_group_label>Comparator 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed SARS-CoV-2 (COVID-19) infection by a positive test result&#xD;
&#xD;
          2. Either gender&#xD;
&#xD;
          3. Symptomatic for example fever, dry Cough, difficulty to breathe&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed absence of SARS-CoV-2 (COVID-19) infection by a negative test result&#xD;
&#xD;
          2. Have chronic conditions such as heart disease, liver and kidney failure&#xD;
&#xD;
          3. Pregnant or currently lactating&#xD;
&#xD;
          4. Immunocompromise and/or systemic disease(s)&#xD;
&#xD;
          5. On other antiviral drugs&#xD;
&#xD;
          6. History of allergy to any of the drugs to be administered in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javed Akram, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Health Sciences Lahore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shehnoor Azhar, MPH</last_name>
    <phone>+92 321 4090221</phone>
    <email>shehnoor.azhar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faislabad Medical University</name>
      <address>
        <city>Faisal훮bad</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanif Nagra</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gujranwala Medical College</name>
      <address>
        <city>Gujr훮nw훮la</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maroof Aziz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nawaz Sharif Medical College</name>
      <address>
        <city>Gujr훮t</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szabmu-Pims</name>
      <address>
        <city>Islamabad</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanweer Khaliq</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akram Medical Complex</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shehla Javed</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fatima Jinnah Medical University</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aamir Zaman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Edward Medical University-Mayo Hospital</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalid M Gondal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lahore General Hospital</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farah Sadiq</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Khyber Teaching Hospital</name>
      <address>
        <city>Peshawar</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saadia Ashraf</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rawalpindi Medical University</name>
      <address>
        <city>Rawalpindi</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Umar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sargodha Medical College</name>
      <address>
        <city>Sargodha</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saifullah Goraya</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 4, 2020</study_first_submitted>
  <study_first_submitted_qc>April 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Health Sciences Lahore</investigator_affiliation>
    <investigator_full_name>Shehnoor Azhar</investigator_full_name>
    <investigator_title>Study Coordinator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>On completion of study, investigators are open to participation in planned IPD projects with a prospective registration, subject to appropriate approvals</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

